CN102268406B - Breast carcinoma drug resistance cell lines originated from BCap37, and applications thereof - Google Patents
Breast carcinoma drug resistance cell lines originated from BCap37, and applications thereof Download PDFInfo
- Publication number
- CN102268406B CN102268406B CN 201010502654 CN201010502654A CN102268406B CN 102268406 B CN102268406 B CN 102268406B CN 201010502654 CN201010502654 CN 201010502654 CN 201010502654 A CN201010502654 A CN 201010502654A CN 102268406 B CN102268406 B CN 102268406B
- Authority
- CN
- China
- Prior art keywords
- cell
- drug resistance
- bats
- bads
- breast carcinoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention provides two breast carcinoma drug resistance cell lines originated from the same parent cell BCap37, and applications thereof, wherein the two breast carcinoma drug resistance cell lines comprise a P-gp-dependent breast carcinoma drug resistance cell line and a P-gp-nondependent breast carcinoma drug resistance cell line. The invention provides two novel breast carcinoma drug resistance cell lines comprising Bats-72 and Bads-200, wherein the two breast carcinoma drug resistance cell lines are originated from the BCap37 cell, the Bats-72 cell does not express P-gp protein and the Bads-200 over-expresses the P-gp protein, such that the Bats-72 cell is the P-gp-nondependent breast carcinoma drug resistance cell line, and the Bads-200 is the P-gp-dependent breast carcinoma drug resistance cell line. With the special biological characteristics, the Bats-72 cell and the Bads-200 cell can be widely applicable for studying tumor resistance mechanism, reversing tumor multidrug resistance, extracting tumor drug resistance markers, screening and evaluating novel antitumor drugs, producing monoclonal antibody drugs, and the like, and have high research value and high production and application value, and are expected to produce good research, economic and social benefits.
Description
(1) technical field
The present invention relates to mammary cancer drug-resistant cell strain and application thereof that two strains come from same parental cell BCap37.
(2) background technology
Malignant tumour is to comprise at present one of the Chinese topmost cause of death of in the world many countries (CA Cancer J Clin.2005,55:74-108.).The international oncology annual meetings in 2008 that the World Health Organization (WHO) holds in U.S. Atlanta sound a warning, and will replace cardiovascular diseases to cancer in 2010 becomes the maximum disease of world's death toll.China Ministry of Health statistical information shows, the annual newly-increased tumour patient 160 of China～1,700,000, and existing tumour patient sum is about 4,500,000, the first place that occupies the disease that causes death.Chemotherapy is one of whole world Main Means for the treatment of at present tumour, although the continuous chemotherapeutics that makes new advances of development is also constantly used new chemotherapy regimen, the malignant tumour acquired resistance causes finally treating unsuccessfully.Tumor drug resistance mechanism is very complicated, has again complicated relation between the different drug resistance inversion mechanism.Multidrug resistance (multidrug resistance, MDR) is important mechanisms wherein.Multidrug resistance is the host defence mechanism that tumour cell is avoided the damage of external objectionable impurities, refers to when tumour cell develops immunity to drugs to a kind of chemotherapeutics that also never contacted, structure and the diverse antitumor drug of mechanism of action develop immunity to drugs to other.The antitumor drug of many natural origins such as taxanes, vincristine(VCR) class, anthracycline etc. can induce the cancer cell to produce MDR.
ATP has the dependent drug efflux pumping function of ATP in conjunction with box protein called membrane transporters superfamily (ATP-binding cassette, ABC), and medicine can be pumped cytolemma and reduce drug level in the born of the same parents outward, be the main mechanism of present MDR.Wherein P-gp albumen (P-glyeoprotein, P-gp) is more widely resistance mechanism of at present research.1976, Juliano and Ling found a kind of transmembrane glycoprotein at the Chinese hamster ovary cell with MDR phenotype, are that molecular weight is cross-film phosphoglucoprotein (Biochim Biophys Acta, 1976,455 (1): 152-162.) of 170KD.P-gp overexpression on the tumor cell membrane, after chemotherapeutics and its combination, cause the ATP-binding domain activation, the ATP hydrolysis releases energy, and the P-gp form is changed, when cytotoxicity not yet occurs in medicine, be about to it and pump the extracellular, reduced the concentration of medicine in the cell, so that cell is avoided the toxic action of chemotherapeutics and produced MDR (Biochem Pharmacol, 2002,64 (5-6): 943-948.).At present research is found all can detect the MDR1 gene in human nearly all tumour cell, in the cancerous swellings such as colorectal carcinoma, liver cancer, kidney, carcinoma of the pancreas, neuroblastoma, mammary cancer, ovarian cancer, the esophageal carcinoma, cancer of the stomach, bladder cancer, lung cancer, carcinoma of gallbladder, cholangiocarcinoma, P-gp all has expression in various degree.Whether mdr cell expresses according to P-gp, is divided into P-gp dependent form and non-P-gp dependent form.
Foundation by drug-resistant cell strain is tumor drug resistance model inside and outside the construct further, thus further investigation MDR resistance mechanism, even find the resistance mechanism that other are new.The people such as Yi Wang had once reported the Bcap37 cell of expressing P-gp by the gene constructed height of transfection mdr1 in 2004.The Bcap37 persister of parental generation Bcap37 cell and high expression level P-gp can be used for the screening of P-gp substrate and as model (the World Journal ofGastroenterology 2004 of drugs biodistribution and pharmacokinetics, 10 (9): 1365-1368), but this is to import ectogenic MDR1 gene in the BCap37 cell, has certain limitation.Masashi Takeda etc. filters out DU145 and the PC-3 cell strain of anti-taxol, and analyze its potential Molecular Mechanisms of Resistance (The Prostate 2007 with epigenetics and DNA chip technology, 67:955-967), but had to the drug-resistant cell strain of P-gp dependent form.
(3) summary of the invention
The object of the invention provides mammary cancer drug-resistant cell strain and the application thereof that two strains come from P-gp dependent form and the non-P-gp dependent form of same parental cell BCap37.
The technical solution used in the present invention is:
A kind of non-P-gp dependent form mammary cancer drug-resistant cell strain bast72 is preserved in Chinese Typical Representative culture collection center, the address: China, Wuhan, Wuhan University, 430072, preservation date: on August 17th, 2010, deposit number: CCTCC No:C201065.
A kind of P-gp dependent form mammary cancer drug-resistant cell strain bads200 is preserved in Chinese Typical Representative culture collection center, the address: China, Wuhan, Wuhan University, 430072, preservation date: on August 17th, 2010, deposit number: CCTCC No:C201066.
Cell strain of the present invention adopts " the two rank sieve methods " that reform to obtain, wherein Bats-72 is by depending on " two rank sieve methods " acquisition that the taxol high dosage attack time increases progressively, " two rank sieve methods " acquisition that Bads-200 increases progressively by depending on dose of paclitaxel." two rank sieve methods " is divided into resistance laundering period and consolidation phase.Paying attention to allow tumour cell be adapted to gradually medicine (such as taxol) in the laundering period stimulates, and the survivaling cell after the drug treating that constantly increases; Then be by strengthening medicine irritation intensity, the resistance proterties that is adapted to gradually the medicine irritation survivaling cell being consolidated in the consolidation phase.
The strain of common drug high dosage impact induced drug resistance of tumor cell, it all is fixing impact of short period of time (being generally 1～6 hour), gained cell strain resistance coefficient is not high, the relevant cell characteristic is not outstanding, can be increased to 72h the attack time and depend on " the two rank sieve methods " that the medicine high dosage attack time increases progressively, can significantly improve gained cell strain resistance proterties, persister Bats-72 provided by the invention is 113.5 times of its parental generation BCap37 cell to the resistance of taxol.
The concrete screening of mammary cancer drug-resistant cell strain Bats-72 of the present invention is operating as: the 1) laundering period; The BCap37 cell is with multiplication culture liquid (RPMI-1640 that contains 10% calf serum), 5%CO
2Under 37 ℃ of conditions, when being cultured to 70%～90% adherent rate, remove supernatant, add 200nM taxol nutrient solution (the multiplication culture liquid that contains the 200nM taxol) and impact cultivation 1 hour, remove 200nM taxol nutrient solution, after blank RPMI-1640 washs 2 times, change multiplication culture liquid and cultivate 72-96h amplification survivaling cell.When being expanded to 70%～90% adherent rate to survivaling cell, repeat again to impact cultivation 1 hour 2 times with 200nM taxol nutrient solution, namely altogether finish 3 200nM taxol nutrient solutions and impact cultivation 1 hour, cell called after Bats-1.Further take the Bats-1 cell as the basis, repeat aforesaid operations, change successively screening conditions into 200nM taxol nutrient solution and impact cultivation 2,4,12,24 and 48 hours, obtain successively Bats-2, Bats-4, Bats-12, Bats-24, Bats-48 cell.2) consolidation phase: take the Bats-48 cell as the basis, impact cultivation 72 hours with 200nM taxol nutrient solution, change and grow nutrient solution amplification 48h, repeat 10 times, must be to the Bats-72 cell.
And the strain of common drug dosage escalation revulsion screening drug resistance of tumor cell needs nearly year at least, can greatly reduce screening time and depend on " the two rank sieve methods " that drug dose increases progressively, persister Bads-200 provided by the invention only needs about 3 months, is 1137.5 times of its parental generation BCap37 cell to the resistance of taxol.
The concrete screening of mammary cancer drug-resistant cell strain Bads-200 of the present invention is operating as: the 1) laundering period; BCap37 cell multiplication culture liquid, 5%CO
2Under 37 ℃ of conditions, when being cultured to the 70%-90% adherent rate, remove supernatant, adding 5nM taxol nutrient solution (the multiplication culture liquid that contains the 5nM taxol) continues to cultivate 72 hours, remove 5nM taxol nutrient solution, after blank RPMI-1640 washs 2 times, change multiplication culture liquid and cultivate 48-72h amplification survivaling cell.When being expanded to the 70%-90% adherent rate to survivaling cell, repeat again to continue to cultivate 72 hours 2 times with 5nM taxol nutrient solution, namely altogether finish 3 5nM taxol nutrient solutions and continue to cultivate cell called after Bads-5 72 hours.Further take the Bads-5 cell as the basis, repeat aforesaid operations, change successively screening conditions into 10nM, 20nM, 50nM, 100nM taxol nutrient solution continue to cultivate 72 hours, obtain successively Bads-10, Bads-20, Bads-50, Bads-100 cell.2) consolidation phase: take the Bads-100 cell as the basis, continue to cultivate with 200nM taxol nutrient solution always, must be to the Bads-200 cell.
Described mammary cancer drug-resistant cell strain bast72 or bads200 can be used for the inside and outside tumor drug resistance model of construct, further can be used for screening new antitumor drug.
The invention provides two kinds of Novel breast gland cancer drug-resistant cell strain Bats-72 and Bads-200, both all originate from the BCap37 cell, and Bats-72 does not express P-gp albumen, and Bads-200 crosses expression P-gp.This shows that Bats-72 right and wrong P-gp relies on drug-resistant cell strain, and Bads-200 is the drug-resistant cell strain of P-gp dependent form.This distinctive biological characteristics makes it can be widely used in studying tumor drug resistance mechanism and reverse multiple drug resistance of tumor, extract the production of tumor drug resistance mark, screening and assessment novel tumor medicine, monoclonal antibody drug etc., have the value that higher research and production are used, expection can produce good scientific research, economic and social benefit.
(4) description of drawings
Fig. 1 is BCap37, and Bats-72 and Bads-200 cell are being inverted the rear photo just putting the microscopically shooting of light microscopic and Giemsa dyeing;
Fig. 2 is BCap37, and Bats-72 and Bads-200 cell growth curve detect;
Fig. 3 taxol is to BCap37, and Bats-72 and Bads-200 cytotoxicity detect;
Fig. 4 is BCap37, Bats-72 and Bads-200 cell P-gp detection of expression; Wherein positive control is MCF7/ADR;
Fig. 5 is Docetaxel, vinorelbine, and Zorubicin, Etoposide, 5 FU 5 fluorouracil, cis-platinum, methotrexate, gemzar is to BCap37, and the cytotoxicity of Bats-72 and Bads-200 cell detects.
(5) embodiment
The present invention is described further below in conjunction with specific embodiment, but protection scope of the present invention is not limited in this:
Embodiment 1:BCap37, Bats-72 and Bads-200 morphocytology detect
(1) experiment material:
Cell strain: taxol sensitive cells strain BCap37 (ordering from Chinese Academy of Sciences's Shanghai cell bank).Two kinds of novel cell strain Bats-72 (CCTCC No:C201065) and Bads-200 (CCTCC No:C201066);
Reagent consumptive material: RPMI-1640 (the lucky promise biological medicine technology in Hangzhou company limited), super new-born calf serum (Shanghai Excell Biology Product Co., Ltd.), basic culture solution (RPMI-1640 that contains 10% new-born calf serum), screening and culturing liquid (basic culture solution that contains the 200nM taxol), Giemsa staining kit (source, Shanghai leaf bio tech ltd), 35mm culture dish (Corning); Instrument: inverted microscope, just putting microscope, cell culture incubator, Bechtop.
(2) experimental technique
BCap37, Bats-72 and Bads-200 are inoculated in respectively the 35mm culture dish, and BCap37 and Bats-72 use basic culture solution, and Bads-200 screening and culturing liquid was cultivated respectively 72 hours, changed fresh basic culture solution, observed on the inverted microscope, took pictures.
Remove nutrient solution, PBS washing 2 times, Giemsa dyes (fully according to the test kit operation instructions), is just putting microscopically and is observing, and takes pictures.
(3) experimental result
The results are shown in Figure 1, compare with parental cell BCap37, the Bats-72 cell volume increases, and iuntercellular is apart from increase, and clonal growth is relatively loose; Bads-200 morphology and BCap37 difference are little, and clonal growth is relatively tightr, and the clone edge is relatively more regular.
(4) conclusion
Change to some extent than BCap37 on Bats-72 and the Bads-200 cellular form.
Embodiment 2:BCap37, Bats-72 and Bads-200 cell growth curve detect
(1) experiment material
Cell strain: with embodiment 1;
Reagent consumptive material: RPMI-1640 (the lucky promise in Hangzhou), 0.25% pancreatin (the lucky promise in Hangzhou), super new-born calf serum (Shanghai Yi Kesai), basic culture solution (RPMI-1640 that contains 10% new-born calf serum), screening and culturing liquid (basic culture solution that contains the 200nM taxol), 100mm culture dish (Corning), 6 orifice plates (Corning);
Instrument: inverted microscope, cell culture incubator, Bechtop, haemocytometer.
(2) experimental technique
BCap37, Bats-72 and Bads-200 are inoculated in the 100mm culture dish, BCap37 and Bats-72 use basic culture solution, Bads-200 cultivated respectively 72 hours with screening and culturing liquid, 0.25% trysinization, collecting cell, cell counting, the single cell suspension of 20000/ml of preparation concentration, respectively every hole inoculation 2ml single cell suspension to 56 orifice plate, every total cell count is 40000.Change fresh basic culture solution according to situation, guarantee the sufficient nutrient composition, respectively at 24,48,72,96,120,144,168,196,240 hours, digest 3 porocytes counting, average, draw growth curve, and calculate cell doubling time.
(3) experimental result
The results are shown in Figure 2, parental cell BCap37 propagation was the fastest, with multiplication speed growth in average per 21.6 hours; The Bads-200 cell took second place, with multiplication speed growth in average per 26.2 hours; The Bats-72 cell proliferation rate was relatively the slowest, with multiplication speed growth in average per 39.4 o'clock;
(4) conclusion
Bats-72 and Bads-200 have slowing down in various degree with respect to parental cell BCap37 rate of propagation.
Embodiment 3: taxol is to BCap37, and Bats-72 and Bads-200 cytotoxicity detect.
(1) experiment material
Cell strain: taxol sensitive cells strain BCap37, two kinds of novel cell strain Bats-72 and Bads-200 reagent consumptive material: RPMI-1640 (the lucky promise in Hangzhou), 0.25% pancreatin (the lucky promise in Hangzhou), super new-born calf serum (Shanghai Yi Kesai), basic culture solution (RPMI-1640 that contains 10% new-born calf serum), screening and culturing liquid (basic culture solution that contains the 200nM taxol), 100mm culture dish (Corning), 96 orifice plates (Corning), DMSO (Shanghai traditional Chinese medicines), MTT, taxol.
Instrument: cell culture incubator, Bechtop, haemocytometer, microplate reader.
(2) experimental technique
BCap37, Bats-72 and Bads-200 are inoculated in the 100mm culture dish, BCap37 and Bats-72 use basic culture solution, Bads-200 cultivated respectively 72 hours with screening and culturing liquid, 0.25% trysinization, collecting cell, cell counting, the single cell suspension of 20000/ml of preparation concentration, respectively every hole inoculation 0.2ml single cell suspension to 96 orifice plate, every total cell count is 4000, cultivates liquid, add taxol treatment, BCap37 cell concentration for the treatment of is 0,1,2,5,10,20,50,100,200,500nM.Bats-72 and Bads200 cell concentration for the treatment of be (05,10,20,50,100,200,500,1000,2000,5000nM taxol treatment 72h, remove supernatant, add 0.2ml DMSO, microplate reader 570nM wavelength detects the OD value.
(3) experimental result
The results are shown in Figure 3, taxol is respectively 4,454 and 4550nM to the IC50 of BCap37, Bats-72 and Bads-200 cell, and the resistance coefficient of Bats-72 is that the resistance coefficient of 113.5, Bads-200 is 1137.5.
(4) conclusion
With respect to BCap37, Bats-72 and Bads-200 have produced tolerance in various degree to taxol.Embodiment 4: Docetaxel, and vinorelbine, Zorubicin, Etoposide, 5 FU 5 fluorouracil, cis-platinum, methotrexate, gemzar is to BCap37, and the cytotoxicity of Bats-72 and Bads-200 cell detects.
(1) experiment material
Cell strain: taxol sensitive cells strain BCap37, two kinds of novel cell strain Bats-72 and Bads-200 reagent consumptive material: RPMI-1640 (the lucky promise in Hangzhou), 0.25% pancreatin (the lucky promise in Hangzhou), super new-born calf serum (Shanghai Yi Kesai), basic culture solution (RPMI-1640 that contains 10% new-born calf serum), screening and culturing liquid (basic culture solution that contains the 200nM taxol), 100mm culture dish (Corning), 96 orifice plates (Corning), DMSO (Shanghai traditional Chinese medicines), MTT, Docetaxel, vinorelbine, Zorubicin, Etoposide, 5 FU 5 fluorouracil, cis-platinum, methotrexate, gemzar (Gemzer); Instrument: cell culture incubator, Bechtop, haemocytometer, microplate reader.
(2) experimental technique
BCap37, Bats-72 and Bads-200 are inoculated in the 100mm culture dish, BCap37 and Bats-72 use basic culture solution, Bads-200 cultivated respectively 72 hours with screening and culturing liquid, 0.25% trysinization, collecting cell, cell counting, the single cell suspension of 20000/ml of preparation concentration, respectively every hole inoculation 0.2ml single cell suspension to 96 orifice plate, every total cell count is 4000, cultivates liquid, add drug treating and process, it is as follows to process final concentration: Docetaxel is 0,1,2,5,10,20,50,100,200,500,1000,2000, and 5000nM; Vinorelbine is 0,10,20,50,100,200,500,1000,2000 and 5000nM; Zorubicin is 0,20,50,100,200,500,1000,2000,5000 and 10000nM; Etoposide is 0,0.5,1,2,5,10,20,50,100 and 200uM; 5 FU 5 fluorouracil is 0,0.5,1,2,5,10,20,50,100 and 200uM; Cis-platinum is 0,20,50,100,200,500,1000,2000,5000 and 10000nM; Methotrexate is 0,1,2,5,10,20,50,100,200 and 500nM; Gemzar is 5,10,20,50,100,200,500,1000 and 2000nM.Drug treating 72h removes supernatant, adds 0.2ml DMSO, and microplate reader 570nM wavelength detects the OD value.
(3) experimental result
Experimental result is shown in Fig. 4 and table 1, Bats-72 and Bads-200 tolerate Docetaxel, vinorelbine, Zorubicin, Etoposide, 5 FU 5 fluorouracil, cis-platinum are not tolerated, but Bats-72 are to methotrexate, the gemzar tolerance, Bads-200 does not but tolerate methotrexate, gemzar;
The IC50 of BCap37Bats-72 and Bads-200 cell is respectively 4,454 and 4550nM, and the resistance coefficient of Bats-72 is that the resistance coefficient of 113.5, Bads-200 is 1137.5.
(4) conclusion
Bats-72 and Bads-200 are the selectivity multidrug resistance cell strain, and both resistances there are differences, and be capable of being combined for the screening of new antitumor drug and the research of antitumor drug resistance mechanism.
Embodiment 5:BCap37, Bats-72 and Bads-200P-gp morphocytology detect
(1) experiment material
Cell strain: taxol sensitive cells strain BCap37, two kinds of novel cell strain Bats-72 and Bads-200, P-gp positive cell strain MCF7/ADR (ordering from Chinese Academy of Sciences's Shanghai cell bank).
Reagent consumptive material: RPMI-1640 (the lucky promise in Hangzhou), 0.25% pancreatin (the lucky promise in Hangzhou), super new-born calf serum (Shanghai Yi Kesai), basic culture solution (RPMI-1640 that contains 10% new-born calf serum), screening and culturing liquid (basic culture solution that contains the 200nM taxol), PBS, Tween-20,100mm culture dish (Corning), protein lysate (green the skies Bioisystech Co., Ltd), BCA protein quantification test kit (green the skies Bioisystech Co., Ltd), primary antibodie anti-P-gp (Santa Cruz, sc-55510), two anti-(Santa Cruz, sc-2005), the ECL test kit, the development camera obscura, X-film, 0.45um pvdf membrane.
Instrument: cell culture incubator, Bechtop, microplate reader.
(2) experimental technique
Cell is inoculated in the 100mm culture dish, cultivate Cap37 and Bats-72 and use basic culture solution, Bads-200 cultivated respectively 72 hours with screening and culturing liquid, 0.25% trysinization, collecting cell adds respectively 0.15～0.3ml cell pyrolysis liquid, ice bath cracking 30 minutes, centrifugal 30 minutes of 12000g gets supernatant.Carry out determination of protein concentration by BCA protein quantification test kit operation instructions.Prepare 7.5% concentration separation gel, loading 40ug protein content, SDS-PAGE operation, 100V, under 150 minutes conditions, with protein delivery to the 0.45um pvdf membrane.5% skimmed milk sealing 1 hour, 4 ℃ of hatchings of primary antibodie are spent the night, and two anti-room temperature hatchings 3 hours are developed by the operation of ECL test kit.
(3) experimental result
It is the same with parental cell BCap37 to the results are shown in Figure 5, Bats-72, and negative for P-gp, Bads-200 is high expression level P-gp then.
(4) conclusion
Bats-72 right and wrong P-gp relies on drug-resistant cell strain, and Bads-200 is the drug-resistant cell strain that P-gp relies on.
Claims (4)
1. a non-P-gp dependent form mammary cancer drug-resistant cell strain bast72 is preserved in Chinese Typical Representative culture collection center, the address: China, Wuhan, Wuhan University, 430072, preservation date: on August 17th, 2010, deposit number: CCTCC No:C201065.
2. a P-gp dependent form mammary cancer drug-resistant cell strain bads200 is preserved in Chinese Typical Representative culture collection center, the address: China, Wuhan, Wuhan University, 430072, preservation date: on August 17th, 2010, deposit number: CCTCC No:C201066.
3. mammary cancer drug-resistant cell strain bast72 as claimed in claim 1 or 2 or the bads200 application in the tumor drug resistance model inside and outside construct.
4. mammary cancer drug-resistant cell strain bast72 as claimed in claim 1 or 2 or the application of bads200 in screening antineoplastic drugs.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201010502654 CN102268406B (en) | 2010-10-11 | 2010-10-11 | Breast carcinoma drug resistance cell lines originated from BCap37, and applications thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201010502654 CN102268406B (en) | 2010-10-11 | 2010-10-11 | Breast carcinoma drug resistance cell lines originated from BCap37, and applications thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102268406A CN102268406A (en) | 2011-12-07 |
| CN102268406B true CN102268406B (en) | 2013-03-13 |
Family
ID=45050870
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201010502654 Expired - Fee Related CN102268406B (en) | 2010-10-11 | 2010-10-11 | Breast carcinoma drug resistance cell lines originated from BCap37, and applications thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102268406B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103263676A (en) * | 2013-02-07 | 2013-08-28 | 魏敏杰 | Method for reversing drug resistance of breast cancer by using miR-487a |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1687405A (en) * | 2005-04-22 | 2005-10-26 | 李红霞 | Drug resistant cell strain of human oophoroma and culturing method |
-
2010
- 2010-10-11 CN CN 201010502654 patent/CN102268406B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1687405A (en) * | 2005-04-22 | 2005-10-26 | 李红霞 | Drug resistant cell strain of human oophoroma and culturing method |
Non-Patent Citations (6)
| Title |
|---|
| Establishment of a P-glycoprotein substrate screening model and its preliminary application;Yi Wang等;《World Journal of Gastroenterology》;20040531;第10卷(第9期);1365-1368 * |
| Masashi Takeda等.The Establishmentof Two Paclitaxel-Resistant ProstateCancerCell Lines andtheMechanisms of Paclitaxel ResistancewithTwoCell Lines.《The Prostate》.2007,第67卷(第9期),955-967页. |
| The Establishmentof Two Paclitaxel-Resistant ProstateCancerCell Lines andtheMechanisms of Paclitaxel ResistancewithTwoCell Lines;Masashi Takeda等;《The Prostate》;20070615;第67卷(第9期);955-967页 * |
| Yi Wang等.Establishment of a P-glycoprotein substrate screening model and its preliminary application.《World Journal of Gastroenterology》.2004,第10卷(第9期),1365-1368. |
| 人乳腺癌细胞MCF-7紫杉醇耐药细胞株的建立及其耐药机制的研究;张小平;《中国优秀硕士学位论文全文数据库医药卫生科技辑》;20090315(第3期);论文正文 * |
| 张小平.人乳腺癌细胞MCF-7紫杉醇耐药细胞株的建立及其耐药机制的研究.《中国优秀硕士学位论文全文数据库医药卫生科技辑》.2009,(第3期),论文正文. |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102268406A (en) | 2011-12-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gong et al. | Arabinogalactan derived from Lycium barbarum fruit inhibits cancer cell growth via cell cycle arrest and apoptosis | |
| Shokoohinia et al. | Potential anticancer properties of osthol: A comprehensive mechanistic review | |
| Huang et al. | Prophylactic administration of fucoidan represses cancer metastasis by inhibiting vascular endothelial growth factor (VEGF) and matrix metalloproteinases (MMPs) in Lewis tumor-bearing mice | |
| Feng et al. | Immunomodulatory effects of Lycium barbarum polysaccharide extract and its uptake behaviors at the cellular level | |
| Jiao et al. | Anticancer activity of Amauroderma rude | |
| He et al. | Anticancer action and mechanism of ergosterol peroxide from Paecilomyces cicadae fermentation broth | |
| Ren et al. | Marine natural products: A potential source of anti-hepatocellular carcinoma drugs | |
| Xia et al. | Delivery of doxorubicin for human cervical carcinoma targeting therapy by folic acid-modified selenium nanoparticles | |
| CN104140953B (en) | Breast cancer multidrug-resistant cell strain constructed by virtue of epirubicin induction as well as construction method and application thereof | |
| Qi et al. | Paeoniflorin inhibits macrophage-mediated lung cancer metastasis | |
| Fan et al. | Mechanism of modulation through PI3K-AKT pathway about Nepeta cataria L.’s extract in non-small cell lung cancer | |
| Wang et al. | Marine bacterial polysaccharide EPS11 inhibits cancer cell growth and metastasis via blocking cell adhesion and attenuating filiform structure formation | |
| Sung et al. | The anti-cancer effect of linusorb B3 from flaxseed oil through the promotion of apoptosis, inhibition of actin polymerization, and suppression of Src activity in glioblastoma cells | |
| Safarpour et al. | Supernatant metabolites from halophilic archaea to reduce tumorigenesis in prostate cancer in-vitro and in-vivo | |
| Ibiyeye et al. | Cockle shell-derived aragonite CaCO3 nanoparticles for co-delivery of doxorubicin and thymoquinone eliminates cancer stem cells | |
| Li et al. | Nitric oxide and hydrogen peroxide signaling in extractive Shiraia fermentation by Triton X-100 for hypocrellin A production | |
| Xia et al. | Preparation, cellular uptake and angiogenic suppression of shikonin-containing liposomes in vitro and in vivo | |
| He et al. | Polysaccharide-peptide from Trametes versicolor: the potential medicine for colorectal cancer treatment | |
| Wang et al. | Saponins extracted from tea (Camellia sinensis) flowers induces autophagy in ovarian cancer cells | |
| Chen et al. | Ginsenoside Rh4 suppresses metastasis of Esophageal Cancer and expression of c-Myc via targeting the Wnt/β-Catenin signaling pathway | |
| Kochan et al. | Panax quinquefolium L. ginsenosides from hairy root cultures and their clones exert cytotoxic, genotoxic and pro-apoptotic activity towards human colon adenocarcinoma cell line Caco-2 | |
| CN102268406B (en) | Breast carcinoma drug resistance cell lines originated from BCap37, and applications thereof | |
| Yan et al. | Discovery of GOT1 inhibitors from a marine-derived aspergillus terreus that act against pancreatic ductal adenocarcinoma | |
| Zhang et al. | A mechanism of isoorientin-induced apoptosis and migration inhibition in gastric cancer AGS cells | |
| Alves et al. | The advances in glioblastoma on-a-chip for therapy approaches |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130313 Termination date: 20141011 |
|
| EXPY | Termination of patent right or utility model |